Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
TAK compared with OVV: revenue, margins and what each company keeps, and the suppliers and customers both name
TAK
Takeda Pharmaceutical Co Ltd
Change
Mkt cap
Revenue
Revenue
OVV
Ovintiv Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
TAK
Takeda Pharmaceutical Co Ltd
vs
OVV
Ovintiv Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
TAK, solid
OVV, dashed
Supply-chain overlap
Revenue flow
TAK: latest quarter not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only TAK
17
NBIX
Neurocrine Biosciences
customer
EXEL
Exelixis
supplier
PTGX
Protagonist Therapeutics
supplier
DNLI
Denali Therapeutics
supplier
13 more · TAK chain
›
Shared
0
No shared counterparties.
Only OVV
6
CUZ
Cousins Properties
supplier
EPM
Evolution Petroleum
customer
—
McDaniel & Associates Consultants
unlisted
supplier
—
Netherland, Sewell & Associates
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
unlisted
supplier
2 more · OVV chain
›
TAK
Takeda Pharmaceutical Co Ltd
Change
20.92
▲
+4.55%
· post 20.93
Mkt cap
$36.0B
Revenue
—
Revenue
—
OVV
Ovintiv Inc.
Change
72.61
▲
+1.46%
· post 72.62
Closed
Oct 30 '26
Mkt cap
$20.0B
Revenue
$3.0B
Q2 FY26
Revenue
$8.9B
FY25
vs
Compare
Closed
Oct 30 '26
TAK
Takeda Pharmaceutical Co Ltd
vs
OVV
Ovintiv Inc.
20.92
▲
+4.55%
post 20.93
Price
72.61
▲
+1.46%
post 72.62
$36.0B
Mkt cap
$20.0B
—
Revenue
$3.0B
Q2 FY26
—
Revenue
$8.9B
FY25
Change
Change
TAK
20.92
▲
+4.55%
vs
OVV
72.61
▲
+1.46%
Closed
Oct 30 '26